ParkinsonCanadaV1, PascalFrancis, Checkpoint, bibRecord, 000C60

Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys

Identifieur interne : 000C60 ( PascalFrancis/Checkpoint ); précédent : 000C59; suivant : 000C61

Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys

Auteurs : V. D. Doan [Canada] ; R. Grondin [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada]

Source :

Clinical neuropharmacology [ 0362-5664 ] ; 1999.

RBID : Pascal:99-0526518

Descripteurs français

Pascal (Inist)
- Antagoniste dopamine, Antagoniste, Agoniste, Récepteur dopaminergique D1, Stimulant dopaminergique, Récepteur dopaminergique, Comportement, Parkinson maladie, Apomorphine, Lévodopa, Association médicamenteuse, Animal, Singe, Long terme, Voie orale, Latence réponse, Durée action, Dose répétée, Activité biologique, SCH 23390, NNC 010112, Antiparkinsonien.
Wicri :
- topic : Singe.

English descriptors

KwdEn :
- Agonist, Animal, Antagonist, Antiparkinson agent, Behavior, Biological activity, D1 Dopamine receptor, Dopamine agonist, Dopamine antagonist, Dopamine receptor, Drug combination, Duration of action, Levodopa, Long term, Monkey, Multiple dose, Oral administration, Parkinson disease, Response latency.

Affiliations:

Canada

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000D27
to stream PascalFrancis, to step Curation: 001196

Links to Exploration step

Pascal:99-0526518

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effect of the selective D<sub>1</sub>
 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys</title>
<author><name sortKey="Doan, V D" sort="Doan, V D" uniqKey="Doan V" first="V. D." last="Doan">V. D. Doan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Abdallah Hadj Tahar" sort="Abdallah Hadj Tahar" uniqKey="Abdallah Hadj Tahar" last="Abdallah Hadj Tahar">ABDALLAH HADJ TAHAR</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gregoire, L" sort="Gregoire, L" uniqKey="Gregoire L" first="L." last="Gregoire">L. Gregoire</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0526518</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0526518 INIST</idno>
<idno type="RBID">Pascal:99-0526518</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D27</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001196</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000C60</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000C60</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effect of the selective D<sub>1</sub>
 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys</title>
<author><name sortKey="Doan, V D" sort="Doan, V D" uniqKey="Doan V" first="V. D." last="Doan">V. D. Doan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Abdallah Hadj Tahar" sort="Abdallah Hadj Tahar" uniqKey="Abdallah Hadj Tahar" last="Abdallah Hadj Tahar">ABDALLAH HADJ TAHAR</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gregoire, L" sort="Gregoire, L" uniqKey="Gregoire L" first="L." last="Gregoire">L. Gregoire</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Animal</term>
<term>Antagonist</term>
<term>Antiparkinson agent</term>
<term>Behavior</term>
<term>Biological activity</term>
<term>D1 Dopamine receptor</term>
<term>Dopamine agonist</term>
<term>Dopamine antagonist</term>
<term>Dopamine receptor</term>
<term>Drug combination</term>
<term>Duration of action</term>
<term>Levodopa</term>
<term>Long term</term>
<term>Monkey</term>
<term>Multiple dose</term>
<term>Oral administration</term>
<term>Parkinson disease</term>
<term>Response latency</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antagoniste dopamine</term>
<term>Antagoniste</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique D1</term>
<term>Stimulant dopaminergique</term>
<term>Récepteur dopaminergique</term>
<term>Comportement</term>
<term>Parkinson maladie</term>
<term>Apomorphine</term>
<term>Lévodopa</term>
<term>Association médicamenteuse</term>
<term>Animal</term>
<term>Singe</term>
<term>Long terme</term>
<term>Voie orale</term>
<term>Latence réponse</term>
<term>Durée action</term>
<term>Dose répétée</term>
<term>Activité biologique</term>
<term>SCH 23390</term>
<term>NNC 010112</term>
<term>Antiparkinsonien</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0362-5664</s0>
</fA01>
<fA02 i1="01"><s0>CLNEDB</s0>
</fA02>
<fA03 i2="1"><s0>Clin. neuropharmacol.</s0>
</fA03>
<fA05><s2>22</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Effect of the selective D<sub>1</sub>
 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DOAN (V. D.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GRONDIN (R.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ABDALLAH HADJ TAHAR</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>GREGOIRE (L.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BEDARD (P. J.)</s1>
</fA11>
<fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>281-287</s1>
</fA20>
<fA21><s1>1999</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16720</s2>
<s5>354000087950320060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>37 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>99-0526518</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Clinical neuropharmacology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Antagoniste dopamine</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Dopamine antagonist</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Antagonista dopamina</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Antagoniste</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Antagonist</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Antagonista</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Agonist</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Agonista</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Récepteur dopaminergique D1</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>D1 Dopamine receptor</s0>
<s5>04</s5>
<s6>«D1» Dopamine receptor</s6>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Receptor dopaminérgico D1</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Dopamine receptor</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Comportement</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Behavior</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Conducta</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Apomorphine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Association médicamenteuse</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Drug combination</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Asociación medicamentosa</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Animal</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Animal</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Animal</s0>
<s5>16</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Singe</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Monkey</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Mono</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Long terme</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Long term</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Voie orale</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Oral administration</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Vía oral</s0>
<s5>19</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Latence réponse</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Response latency</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Latencia respuesta</s0>
<s5>21</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Durée action</s0>
<s5>22</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Duration of action</s0>
<s5>22</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Duración acción</s0>
<s5>22</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Dose répétée</s0>
<s5>23</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Multiple dose</s0>
<s5>23</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Dosis múltiple</s0>
<s5>23</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>Activité biologique</s0>
<s5>24</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG"><s0>Biological activity</s0>
<s5>24</s5>
</fC03>
<fC03 i1="19" i2="X" l="SPA"><s0>Actividad biológica</s0>
<s5>24</s5>
</fC03>
<fC03 i1="20" i2="X" l="FRE"><s0>SCH 23390</s0>
<s2>FR</s2>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC03 i1="21" i2="X" l="FRE"><s0>NNC 010112</s0>
<s2>FR</s2>
<s4>INC</s4>
<s5>87</s5>
</fC03>
<fC03 i1="22" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
</fC03>
<fC03 i1="22" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
</fC03>
<fC03 i1="22" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>61</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>61</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>61</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>62</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>62</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>62</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>63</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>63</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>63</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>64</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>64</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>64</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>65</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>65</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>65</s5>
</fC07>
<fN21><s1>340</s1>
</fN21>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Doan, V D" sort="Doan, V D" uniqKey="Doan V" first="V. D." last="Doan">V. D. Doan</name>
</noRegion>
<name sortKey="Abdallah Hadj Tahar" sort="Abdallah Hadj Tahar" uniqKey="Abdallah Hadj Tahar" last="Abdallah Hadj Tahar">ABDALLAH HADJ TAHAR</name>
<name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name>
<name sortKey="Gregoire, L" sort="Gregoire, L" uniqKey="Gregoire L" first="L." last="Gregoire">L. Gregoire</name>
<name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C60 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000C60 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:99-0526518
   |texte=   Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys

Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri